Veru (VERU)
NASDAQ:VERU

Veru Stock Analysis & Ratings

Veru Stock Analysis Overview

Smart Score
2
Underperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Veru stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

VERU

VERU Stock Stats

Previous Close$4.69
Open$4.77
Bid0 x 0
Ask0 x 0
Today’s Range$4.52 - $4.9
52-Week Range$4.47 - $24.57
Volume718.23K
Average Volume1.02M
Market Cap$364.14M
Beta0.44
P/E Ratio44.7
EPS0.10
Earnings DateFeb 09, 2022
Ex-Dividend DateApr 28, 2014

Company Description

Veru

Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
Sector
Healthcare
Industry
Biotechnology
CEO
Mitchell S. Steiner
Employees
252
Website
www.verupharma.com
ISIN
US92536C1036
Address
48 NW 25th Street, Miami, FL, 33137, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

VERU FAQ

What was Veru’s price range in the past 12 months?
Veru lowest stock price was $4.47 and its highest was $24.57 in the past 12 months.
    What is Veru’s market cap?
    Veru’s market cap is $364.14M.
      What is Veru’s price target?
      The average price target for Veru is $21.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $21.00 ,the lowest forecast is $21.00. The average price target represents 361.54% Increase from the current price of $4.55.
        What do analysts say about Veru?
        Veru’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Veru’s upcoming earnings report date?
          Veru’s upcoming earnings report date is Feb 09, 2022 which is in 12 days.
            How were Veru’s earnings last quarter?
            Veru released its earnings results on Dec 02, 2021. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.092 by $0.042.
              Is Veru overvalued?
              According to Wall Street analysts Veru’s price is currently Undervalued.
                Does Veru pay dividends?
                Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 5.82%. Veru’s last Quarterly dividend payment was on May 07, 2014. Veru’s upcoming ex-dividend date is Apr 28, 2014
                  What is Veru’s EPS estimate?
                  Veru’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Veru have?
                  Veru has 80,030,000 shares outstanding.
                    What happened to Veru’s price movement after its last earnings report?
                    Veru reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.092. Following the earnings report the stock price went down -12.301%.
                      Which hedge fund is a major shareholder of Veru?
                      Among the largest hedge funds holding Veru’s share is Perceptive Advisors LLC. It holds Veru’s shares valued at 38M.

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis